An ambitious new company focused on radically extending human healthspan using epigenetic reprogramming therapies. Their long term ambition is to rejuvenate tissue throughout the whole body. However, they plan on developing intermediary products first, with the first two indications hypothesized to be ocular disease and immunosenescence. An example of the basic research they will be pursuing is mapping age dependent transcriptional and epigenetic shifts using single cell sRNA/ATACseq.